# Takayuki Yoshino

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/takayuki-yoshino/

## Facts

| Field | Value |
| --- | --- |
| Citations | 52,158 |
| Field | Colorectal Cancer Treatments and Studies |
| h-index | 90 |
| i10-index | 432 |
| Last Known Institution | University of Tsukuba |
| OpenAlex ID | https://openalex.org/A5062748030 |
| ORCID iD | https://orcid.org/0000-0002-0489-4756 |
| Works | 1,576 |

## Researcher papers

Showing 12 of 15.

- [Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer](https://scholariq.org/papers/japanese-society-for-cancer-of-the-colon-and-rectum-jsccr-guidelines-2016-for/)
- [Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer](https://scholariq.org/papers/japanese-society-for-cancer-of-the-colon-and-rectum-jsccr-guidelines-2019-for/)
- [Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer](https://scholariq.org/papers/encorafenib-binimetinib-and-cetuximab-in-i-braf-i-v600e-mutated-colorectal/)
- [Duration of Adjuvant Chemotherapy for Stage III Colon Cancer](https://scholariq.org/papers/duration-of-adjuvant-chemotherapy-for-stage-iii-colon-cancer/)
- [Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study](https://scholariq.org/papers/ramucirumab-versus-placebo-in-combination-with-second-line-folfiri-in-patients/)
- [ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group](https://scholariq.org/papers/esmo-recommendations-on-the-use-of-circulating-tumour-dna-assays-for-patients/)
- [Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS](https://scholariq.org/papers/pan-asian-adapted-esmo-consensus-guidelines-for-the-management-of-patients-with/)
- [Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer](https://scholariq.org/papers/molecular-residual-disease-and-efficacy-of-adjuvant-chemotherapy-in-patients/)
- [Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies](https://scholariq.org/papers/clinical-utility-of-circulating-tumor-dna-sequencing-in-advanced/)
- [Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study](https://scholariq.org/papers/fruquintinib-versus-placebo-in-patients-with-refractory-metastatic-colorectal/)
- [Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With <i>RAS</i> Wild-type, Left-Sided Metastatic Colorectal Cancer](https://scholariq.org/papers/panitumumab-vs-bevacizumab-added-to-standard-first-line-chemotherapy-and-overall/)
- [Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel](https://scholariq.org/papers/validation-of-microsatellite-instability-detection-using-a-comprehensive-plasma/)

## Researcher topics

- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Genetic factors in colorectal cancer](https://scholariq.org/topics/genetic-factors-in-colorectal-cancer/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)

## Researcher university

- [University of Tsukuba](https://scholariq.org/institutions/university-of-tsukuba/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.